197 related articles for article (PubMed ID: 23591110)
1. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3416-20. PubMed ID: 23591110
[TBL] [Abstract][Full Text] [Related]
2. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
[TBL] [Abstract][Full Text] [Related]
3. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
4. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.
de Lera Ruiz M; Zheng J; Berlin MY; McCormick KD; Aslanian RG; West R; Hwa J; Lachowicz J; van Heek M
Bioorg Med Chem Lett; 2013 Nov; 23(21):6004-9. PubMed ID: 24035485
[TBL] [Abstract][Full Text] [Related]
5. Fluorinated non-imidazole histamine H3 receptor antagonists.
Isensee K; Amon M; Garlapati A; Ligneau X; Camelin JC; Capet M; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2009 Apr; 19(8):2172-5. PubMed ID: 19286376
[TBL] [Abstract][Full Text] [Related]
6. [Identification of a HEK-293 cell line containing stably-transfected H3R gene and screening for novel non-imidazole histamine H3 receptor antagonists].
He P; Tan L; Hu W; Dai H; Hu Y; Chen Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 May; 42(3):276-82. PubMed ID: 23801615
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
[TBL] [Abstract][Full Text] [Related]
8. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2013 May; 23(9):2548-54. PubMed ID: 23535326
[TBL] [Abstract][Full Text] [Related]
9. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
10. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Stocking EM; Aluisio L; Atack JR; Bonaventure P; Carruthers NI; Dugovic C; Everson A; Fraser I; Jiang X; Leung P; Lord B; Ly KS; Morton KL; Nepomuceno D; Shah CR; Shelton J; Soyode-Johnson A; Letavic MA
Bioorg Med Chem Lett; 2010 May; 20(9):2755-60. PubMed ID: 20382018
[TBL] [Abstract][Full Text] [Related]
11. Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity.
Incerti M; Flammini L; Saccani F; Morini G; Comini M; Coruzzi M; Barocelli E; Ballabeni V; Bertoni S
ChemMedChem; 2010 Jul; 5(7):1143-9. PubMed ID: 20512794
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel steroidal histamine H
Ledneczki I; Tapolcsányi P; Gábor E; Éles J; Greiner I; Schmidt É; Némethy Z; Kedves RS; Balázs O; Román V; Lévay G; Mahó S
Bioorg Med Chem Lett; 2017 Oct; 27(19):4525-4530. PubMed ID: 28888822
[TBL] [Abstract][Full Text] [Related]
13. Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles.
Walter M; Isensee K; Kottke T; Ligneau X; Camelin JC; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2010 Oct; 20(19):5883-6. PubMed ID: 20727744
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
Zeng Q; Rosenblum SB; Yang Z; Jiang Y; McCormick KD; Aslanian RG; Duguma L; Kozlowski JA; Shih NY; Hey JA; West RE; Korfmacher WA; Berlin M; Boyce CW
Bioorg Med Chem Lett; 2013 Nov; 23(21):6001-3. PubMed ID: 24050887
[TBL] [Abstract][Full Text] [Related]
15. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
[TBL] [Abstract][Full Text] [Related]
16. Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.
Kumar A; Pasam VR; Thakur RK; Singh M; Singh K; Shukla M; Yadav A; Dogra S; Sona C; Umrao D; Jaiswal S; Ahmad H; Rashid M; Singh SK; Wahajuddin M; Dwivedi AK; Siddiqi MI; Lal J; Tripathi RP; Yadav PN
J Med Chem; 2019 May; 62(9):4638-4655. PubMed ID: 30998358
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.
Cole DC; Gross JL; Comery TA; Aschmies S; Hirst WD; Kelley C; Kim JI; Kubek K; Ning X; Platt BJ; Robichaud AJ; Solvibile WR; Stock JR; Tawa G; Williams MJ; Ellingboe JW
Bioorg Med Chem Lett; 2010 Feb; 20(3):1237-40. PubMed ID: 20042333
[TBL] [Abstract][Full Text] [Related]
18. The discovery of potent selective NPY Y(2) antagonists.
Chai W; Wong VD; Nepomuceno D; Bonaventure P; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2013 Jul; 23(14):4141-4. PubMed ID: 23756063
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
Tao M; Raddatz R; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2011 Oct; 21(20):6126-30. PubMed ID: 21906941
[TBL] [Abstract][Full Text] [Related]
20. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
Sadek B; Schwed JS; Subramanian D; Weizel L; Walter M; Adem A; Stark H
Eur J Med Chem; 2014 Apr; 77():269-79. PubMed ID: 24650714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
